Trials / Terminated
TerminatedNCT05362487
Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
Switching COPD Patients From Spiriva® HandiHaler® Maintenance Therapy to Spiriva® Respimat®: a Non-Interventional Real-world clinicAl ouTcome assEssment: NIS PIRATE
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 9 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this non-interventional, observational study is to assess whether changing Chronic Obstructive Pulmonary Disease (COPD) patients from a dry powder inhaler (HandiHaler®) to a soft mist inhaler (Respimat®), without changing the pharmacological compound, will lead to an improvement in Clinical COPD Questionnaire (CCQ) score and in the scores of the three subdomains of CCQ score: symptoms (4 items), functional state (4 items) and mental state (2 items) during a study period of approximately 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Spiriva® Respimat® | Spiriva® Respimat® |
| DEVICE | Spiriva® HandiHaler® | Spiriva® HandiHaler® |
| DRUG | Tiotropium bromide | Tiotropium bromide |
Timeline
- Start date
- 2022-08-05
- Primary completion
- 2023-01-18
- Completion
- 2023-01-18
- First posted
- 2022-05-05
- Last updated
- 2025-02-26
- Results posted
- 2024-07-08
Locations
1 site across 1 country: Switzerland
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05362487. Inclusion in this directory is not an endorsement.